Trump hits long-term pledge as US prices of weight loss drugs slashed
Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.
Therapy Area
J&J’s Caplyta wins MDD approval to extend revenue horizon
Former blockbuster Linzess grows label with paediatric IBS-C approval
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats
AI breakthrough promises earlier prostate cancer diagnosis
ESMO 2025: Sichuan-Kelun moves in breast cancer ADC space
ESMO 2025: Bayer and BI neck and neck in first line HER2+ NSCLC
